GeneQuantum Collaborates with Aimed Bio To Co develop First In Class ADC

 GeneQuantum Healthcare Co., Ltd., a company specializing in site-specific bioconjugation for next generation biotherapeutics, has signed an agreement with a Korean biotech company, Aimed Bio Inc., to co-develop a First-in-Class therapeutic Antibody Drug Conjugate (ADC).  Aimed Bio, a spin-off company from Samsung Medical Center, is focusing on developing innovative antibody-centric drugs for brain diseases with […]